Experienced in Generalized Anxiety Disorder (GAD)

Dr. Susan L. Mcelroy

Psychiatry
Lindner Center Of Hope Professional Associates
4075 Old Western Row Rd, 
Mason, OH 
Accepting New Patients
Experienced in Generalized Anxiety Disorder (GAD)
Lindner Center Of Hope Professional Associates
4075 Old Western Row Rd, 
Mason, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Mcelroy is a Psychiatrist in Mason, Ohio. Dr. Mcelroy is rated as an Experienced provider by MediFind in the treatment of Generalized Anxiety Disorder (GAD). Her top areas of expertise are Bipolar Disorder (BPD), Bulimia, Anorexia, and Major Depression. Dr. Mcelroy is currently accepting new patients.

Her clinical research consists of co-authoring 298 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Generalized Anxiety Disorder (GAD).

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

LINDNER CENTER OF HOPE PROFESSIONAL ASSOCIATES
4075 Old Western Row Rd, Mason, OH 45040

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drug: MYDAYIS
Study Phase: Phase 2
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
Enrollment Status: Completed
Publish Date: March 12, 2025
Intervention Type: Drug, Other
Study Drug: Liraglutide
Study Phase: Phase 2
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Enrollment Status: Completed
Publish Date: May 14, 2020
Intervention Type: Other
View 6 Less Clinical Trials

298 Total Publications

Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World Historical Cohort Study.
Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World Historical Cohort Study.
Journal: medRxiv : the preprint server for health sciences
Published: September 15, 2025
Similar Doctors
Distinguished in Generalized Anxiety Disorder (GAD)
Dr. James B. Shackson
Psychiatry | Geriatrics
Distinguished in Generalized Anxiety Disorder (GAD)
Dr. James B. Shackson
Psychiatry | Geriatrics

Guidestar Eldercare Corp -Oh

990 Bayley Dr, 
Cincinnati, OH 
 (24.9 miles away)
574-546-1900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Shackson is a Psychiatrist and a Geriatrics provider in Cincinnati, Ohio. Dr. Shackson is rated as a Distinguished provider by MediFind in the treatment of Generalized Anxiety Disorder (GAD). His top areas of expertise are Seasonal Affective Disorder (SAD), Major Depression, Generalized Anxiety Disorder (GAD), and Schizophrenia. Dr. Shackson is currently accepting new patients.

Distinguished in Generalized Anxiety Disorder (GAD)
Dr. Otto R. Dueno
Psychiatry | Geriatrics
Distinguished in Generalized Anxiety Disorder (GAD)
Dr. Otto R. Dueno
Psychiatry | Geriatrics

Kettering Independent Medical Group Inc

5350 Lamme Rd, 
Moraine, OH 
 (23.8 miles away)
937-534-4620
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Otto Dueno is a Psychiatrist and a Geriatrics provider in Moraine, Ohio. Dr. Dueno is rated as a Distinguished provider by MediFind in the treatment of Generalized Anxiety Disorder (GAD). His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Generalized Anxiety Disorder (GAD). Dr. Dueno is currently accepting new patients.

Distinguished in Generalized Anxiety Disorder (GAD)
Dr. Amita R. Patel
Psychiatry
Distinguished in Generalized Anxiety Disorder (GAD)
Dr. Amita R. Patel
Psychiatry
1435 Haven Hill Dr, 
Dayton, OH 
 (22.8 miles away)
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Amita Patel is a Psychiatrist in Dayton, Ohio. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Generalized Anxiety Disorder (GAD). Her top areas of expertise are Alzheimer's Disease, Seasonal Affective Disorder (SAD), Major Depression, Vascular Dementia, and Gastrostomy. Dr. Patel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcelroy's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile